Rheumatoid arthritis Trials in Białystok, Poland
Conditions / Rheumatoid arthritis / Białystok, Poland
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
96 total trials for this combination
Showing top 10 of 96 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01709578 | To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) | COMPLETED | PHASE3 |
| NCT02629159 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02889796 | Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate | COMPLETED | PHASE3 |
| NCT03025308 | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01194414 | A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT02675426 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone | COMPLETED | PHASE3 |
| NCT01146652 | Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) | COMPLETED | PHASE3 |
| NCT01061736 | Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients | COMPLETED | PHASE2/PHASE3 |
| NCT03915964 | A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis | COMPLETED | PHASE4 |
| NCT05516758 | A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis | TERMINATED | PHASE2 |